Innate Pharma (IPHYF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 10,188 | 21,773 | 66,714 | 60,765 | 29,226 |
| Gross Profit | 10,188 | 21,773 | 66,714 | 60,765 | 29,226 |
| Operating Expenses | 71,294 | 77,582 | 80,426 | 121,268 | 85,808 |
| Operating Income | -61,105 | -55,809 | -13,712 | -60,503 | -56,582 |
| Interest Expense | 3,530 | 4,301 | 1,986 | 5,606 | 4,729 |
| Other Income | 8,996 | 6,578 | 7,505 | 5,030 | 7,506 |
| Pre-tax Income | -55,639 | -53,533 | -8,193 | -61,079 | -53,805 |
| Net Income Continuous | -55,639 | -53,533 | -8,193 | -61,079 | -53,805 |
| Net Income Discontinuous | N/A | N/A | N/A | -138 | -8,673 |
| Net Income | $-55,639 | $-53,533 | $-8,193 | $-61,217 | $-62,478 |
| EPS Basic Total Ops | -0.62 | -0.66 | -0.10 | -0.77 | -0.78 |
| EPS Basic Continuous Ops | -0.62 | -0.66 | -0.10 | -0.77 | -0.68 |
| EPS Basic Discontinuous Ops | N/A | N/A | N/A | 0.00 | -0.11 |
| EPS Diluted Total Ops | -0.62 | -0.66 | -0.10 | -0.77 | -0.78 |
| EPS Diluted Continuous Ops | -0.62 | -0.66 | -0.10 | -0.77 | -0.68 |
| EPS Diluted Discontinuous Ops | N/A | N/A | N/A | 0.00 | -0.11 |
| EPS Diluted Before Non-Recurring Items | -0.62 | -0.66 | -0.10 | -0.23 | -0.67 |
| EBITDA(a) | $-59,540 | $-53,652 | $-8,202 | $-12,664 | $-51,144 |